Mesna

Educational clinical summary of Mesna for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's specific circumstances, current guidelines, and available evidence. Dosages and protocols are subject to change and should be verified with official prescribing information and institutional guidelines.

Overview

Definition: Mesna (2-mercaptoethane sulfonate sodium) is a synthetic sulfhydryl compound used as a uroprotective agent to prevent hemorrhagic cystitis induced by oxazaphosphorine chemotherapy agents, specifically ifosfamide and high-dose cyclophosphamide. It is an acronym for MercaptoEthane Sulfonate NA (sodium).
Epidemiology: Mesna's use is directly linked to the incidence of cancers treated with ifosfamide or high-dose cyclophosphamide, including various lymphomas, sarcomas, germ cell tumors, and some solid tumors. Hemorrhagic cystitis can occur in 10-40% of patients treated with ifosfamide without prophylaxis and up to 10% with high-dose cyclophosphamide. Mesna significantly reduces this incidence.
Classification: Chemoprotective agent; uroprotectant.

Pathophysiology

Mechanism: Oxazaphosphorine cytotoxic agents, such as ifosfamide and cyclophosphamide, are pro-drugs that are metabolized in the liver by cytochrome P450 enzymes to active alkylating metabolites. A toxic by-product of this metabolism is acrolein. Acrolein is excreted in the urine and is directly toxic to the urothelium, causing irritation, inflammation, and cellular necrosis, leading to hemorrhagic cystitis. Mesna's mechanism of action involves:
1. Selective accumulation in the urine: Mesna is rapidly filtered by the glomeruli and extensively excreted into the urine. Its distribution is largely confined to the intravascular compartment, with minimal systemic tissue distribution.
2. Detoxification of acrolein: In the urinary tract, Mesna's sulfhydryl group forms a stable thioether conjugate with acrolein via a Michael addition reaction, effectively binding and inactivating the urotoxic metabolite. This reaction renders acrolein non-toxic and prevents its interaction with the bladder epithelium.
3. Scavenging of free radicals: Mesna may also act as a sulfhydryl donor, regenerating intracellular glutathione and acting as a free radical scavenger, further contributing to uroprotection.
Risk Factors (for oxazaphosphorine-induced hemorrhagic cystitis mitigated by Mesna):
- High cumulative dose or dose intensity of ifosfamide or cyclophosphamide.
- Prior pelvic irradiation.
- Pre-existing bladder dysfunction or injury.
- Dehydration.
- Renal impairment (leading to higher urinary concentrations of acrolein).
- Concomitant nephrotoxic agents.
- Young age (pediatric patients may be more susceptible).
Protective Factors: Mesna is the primary protective factor against oxazaphosphorine-induced hemorrhagic cystitis. Adequate hydration is a synergistic protective factor, increasing urine flow and diluting toxic metabolites.

Clinical Presentation (Mesna's Adverse Effects & Purpose)

Note: Mesna itself is not a disease entity but a protective agent. This section will focus on its potential adverse effects and the clinical problem it prevents.

Adverse Effects of Mesna

Cardinal Features: Mesna is generally well-tolerated. The most common adverse effects are mild and transient, often overshadowed by the toxicity of the chemotherapy.
- Nausea and Vomiting (most common, often managed with antiemetics for chemotherapy)
- Diarrhea
- Headache
- Flushing
- Rash
- Hypotension (rare, usually with rapid IV infusion)
- Dizziness, somnolence (rare)
Early Signs: Nausea, vomiting, and diarrhea may begin shortly after administration.
Advanced Signs: Severe adverse effects are rare, but include allergic reactions (bronchospasm, dyspnea, anaphylaxis).
Atypical Presentations: Rarely, transient elevation of liver enzymes or mild elevations in creatine phosphokinase (CPK) have been reported.

Physical Examination (Related to Mesna Adverse Effects)

Inspection: Skin rash, flushing.
Palpation: Not typically relevant unless assessing for dehydration due to GI side effects.
Special Tests: None specific for Mesna adverse effects. Assessment would be clinical based on reported symptoms.

Diagnostic Approach (Assessing Need for Mesna and Monitoring Efficacy)

Note: This section focuses on the rationale for using Mesna and monitoring its effectiveness in preventing hemorrhagic cystitis.

History Taking (For Chemotherapy Patients Requiring Mesna)

Key Questions:
- Current chemotherapy regimen (ifosfamide, high-dose cyclophosphamide?).
- Planned chemotherapy dose and duration.
- History of prior chemotherapy or radiation to the pelvis.
- Pre-existing renal or bladder dysfunction.
- Hydration status and fluid intake.
- Allergies, especially to sulfhydryl compounds.
Red Flags (Indicating a need for Mesna or potential complications if not used):
- Administration of ifosfamide (Mesna is almost always mandatory).
- Administration of cyclophosphamide at doses ≥ 1.0-1.5 g/m² (or higher, depending on institutional protocol).
- Patient at high risk for hemorrhagic cystitis (e.g., prior pelvic radiation).

Laboratory Tests (Monitoring for Efficacy/Complications)

First-Line:
- Urinalysis with microscopy: To monitor for hematuria (red blood cells) during and after chemotherapy. This is the primary marker for early hemorrhagic cystitis, indicating Mesna may not be fully protective or an inadequate dose was given.
- Renal function tests (Creatinine, BUN): To assess kidney function, which influences drug excretion and overall fluid management.
Confirmatory: N/A for Mesna itself. Hemorrhagic cystitis diagnosis is clinical and by urinalysis.
Monitoring:
- Daily urinalysis during and for several days after oxazaphosphorine administration.
- Fluid balance monitoring (intake and output).
- Electrolytes (if significant vomiting/diarrhea or large fluid shifts).

Imaging (Not for Mesna, but for Hemorrhagic Cystitis if it occurs)

Recommended: Generally not required for Mesna administration. If hemorrhagic cystitis is severe or persistent despite Mesna, imaging might be considered:
- Ultrasound of bladder: To assess for clots or bladder wall thickening.
- Cystoscopy: In severe, refractory cases to identify bleeding sites or rule out other causes of hematuria.
Advanced: CT or MRI of the pelvis may be used in complicated cases to rule out other pathology but are not routine for Mesna monitoring.

Management

Acute Management (Mesna Administration)

Immediate: Mesna should be administered immediately prior to or concurrently with the first dose of ifosfamide or high-dose cyclophosphamide.
Stabilization: Ensure adequate hydration (oral or intravenous) alongside Mesna administration. This enhances Mesna's protective effect by increasing urinary flow and diluting metabolites.
Emergency: Mesna is a prophylactic agent; its administration is part of planned chemotherapy, not an emergency intervention in itself. However, if hemorrhagic cystitis develops despite Mesna, symptomatic management (e.g., bladder irrigation, analgesia, potentially transfusions for severe hematuria) is initiated.

Chronic Management

Pharmacological (Mesna Dosages): Mesna can be administered intravenously (IV) or orally (PO). Oral Mesna has approximately 50% bioavailability compared to IV.
- Ifosfamide Prophylaxis (most common use):
  - Standard IV Protocol: Total daily Mesna dose is typically 60% of the total ifosfamide dose, divided into multiple doses.
    - Bolus Dosing: Mesna 20% of the ifosfamide dose given IV immediately before ifosfamide, then Mesna 20% of the ifosfamide dose given IV at 4 hours and 8 hours after the ifosfamide dose. (e.g., for Ifosfamide 1.2 g/m² over 30 min, Mesna 240 mg/m² at 0, 4, 8 hours).
    - Continuous Infusion: Mesna 20% of the ifosfamide dose as an IV bolus, followed by a continuous IV infusion of Mesna at 40% of the ifosfamide dose over the next 24 hours. The Mesna infusion typically starts at the same time as ifosfamide and continues for at least 12-24 hours after the ifosfamide infusion is completed. (e.g., for Ifosfamide 1.2 g/m² over 1 hour, Mesna 240 mg/m² bolus, then 480 mg/m² over 24 hours, continuing for 12 hours post-ifosfamide).
  - Oral Protocol (if available and tolerated): Total daily oral Mesna is typically 100-160% of the total ifosfamide dose. Often given 2 hours before ifosfamide, then 2 and 6 hours after ifosfamide, or in divided doses every 3-4 hours. Oral Mesna is generally used for patients receiving ifosfamide as an outpatient.
- High-Dose Cyclophosphamide Prophylaxis:
  - Used for cyclophosphamide doses typically > 1.0-1.5 g/m².
  - Standard IV Protocol: Total daily Mesna dose is typically 60-100% of the cyclophosphamide dose, divided.
    - Mesna 20% of the cyclophosphamide dose IV immediately before cyclophosphamide, then Mesna 20% of the cyclophosphamide dose at 3, 6, 9, 12 hours after the cyclophosphamide dose, or similar schedules.
    - Continuous Infusion: Mesna 20% of cyclophosphamide dose as a bolus, followed by 60-80% of cyclophosphamide dose over 24 hours, continuing for 12-24 hours post-cyclophosphamide.
- Dosage Adjustments:
  - Renal Impairment: No specific dose adjustment guidelines from manufacturers, but caution advised due to renal excretion. Adequate hydration is paramount.
  - Hepatic Impairment: No specific dose adjustment guidelines.
Non-pharmacological:
- Hydration: Aggressive intravenous or oral hydration (e.g., 2-3 liters/m²/day of IV fluids) is crucial to maintain a high urine flow rate, which dilutes urotoxic metabolites and enhances Mesna's action. Diuresis should aim for a urine output of >100 mL/hr in adults.
- Frequent voiding: Encouraging patients to empty their bladder frequently helps prevent prolonged contact of urotoxic metabolites with the bladder wall.
Monitoring: Continuous monitoring for signs of hemorrhagic cystitis (especially hematuria) throughout the chemotherapy cycle and for 24-72 hours after the last dose of ifosfamide/cyclophosphamide. Fluid balance monitoring.

Treatment Algorithms

First-Line (for Ifosfamide/High-Dose Cyclophosphamide): Concurrent administration of Mesna with adequate hydration.
- Ifosfamide: Mesna is mandatory with all doses of ifosfamide due to the high risk of severe hemorrhagic cystitis.
- Cyclophosphamide: Mesna is typically used for doses ≥ 1.0-1.5 g/m² (or higher depending on protocol). For standard lower doses, hyperhydration alone might be sufficient, but Mesna provides added protection.
Second-Line: If hemorrhagic cystitis develops despite Mesna, the management shifts to supportive care (e.g., continuous bladder irrigation with normal saline, electrocautery for bleeding, urologic consultation). This indicates a failure of prophylactic Mesna, not an alternative Mesna regimen.
Refractory Cases (of Hemorrhagic Cystitis): Beyond the scope of Mesna's primary role, but may involve intravesical instillation of agents like formalin, silver nitrate, or hyperbaric oxygen therapy in severe, life-threatening hematuria.

Complications (Adverse Effects of Mesna)

Common:
- Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.
- Central Nervous System: Headache, dizziness, somnolence (often mild).
- Dermatologic: Rash, flushing.
- General: Malaise, fever.
Serious:
- Hypersensitivity Reactions: Rare but can be severe, including anaphylaxis, bronchospasm, dyspnea, and rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis). More common in patients with autoimmune disorders or prior Mesna exposure.
- Cardiovascular: Hypotension (especially with rapid IV infusion), tachycardia.
- Hematologic: Transient reductions in lymphocyte counts or mild eosinophilia have been reported, but Mesna generally does not cause myelosuppression.
Long-term: Mesna itself is rapidly eliminated and does not typically cause long-term adverse effects.

Prognosis (Mesna's Impact)

Factors: Mesna significantly improves the prognosis for patients receiving oxazaphosphorine chemotherapy by preventing or significantly reducing the incidence and severity of hemorrhagic cystitis. This allows for completion of planned chemotherapy courses with fewer dose delays or reductions due to bladder toxicity.
Survival: Mesna does not directly impact cancer survival but prevents a serious, potentially life-threatening complication that could necessitate treatment interruption or even be fatal in extreme cases (due to severe blood loss).
Quality of Life: By preventing debilitating symptoms like dysuria, frequency, and gross hematuria, Mesna preserves the patient's quality of life during and after chemotherapy.

Prevention (Mesna's Primary Role)

Primary: Mesna is the primary prevention for oxazaphosphorine-induced hemorrhagic cystitis. It should be administered prophylactically with all ifosfamide regimens and high-dose cyclophosphamide regimens.
Secondary: Not applicable as Mesna prevents the initial occurrence.
Tertiary: Not applicable. Mesna is a prophylactic agent. If hemorrhagic cystitis develops, tertiary prevention focuses on managing the complication.

Special Populations

Pediatric: Mesna dosing principles are similar to adults, based on the ifosfamide/cyclophosphamide dose. Adequate hydration is particularly critical in children. Children may be more susceptible to ifosfamide-induced encephalopathy and renal tubular dysfunction, making Mesna's protective role even more important.
Geriatric: No specific dose adjustments for Mesna based solely on age. However, elderly patients may have reduced renal function, which can affect the excretion of chemotherapy metabolites and Mesna. Careful monitoring of renal function and hydration status is essential. They may also be more susceptible to dehydration.
Pregnancy: Pregnancy Category B. Animal studies have shown no evidence of impaired fertility or harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Mesna should be used during pregnancy only if clearly needed and the potential benefits outweigh the potential risks. Given that it is used with highly teratogenic chemotherapy, this is often a complex risk-benefit discussion.
Comorbidities:
- Renal Impairment: While Mesna is renally excreted, no specific dose adjustments are typically made. However, patients with severe renal impairment may have reduced clearance of the chemotherapy itself and its toxic metabolites, increasing the overall risk of toxicity. Close monitoring of urine output and hematuria is crucial.
- Hypersensitivity: Patients with a known hypersensitivity to Mesna or other sulfhydryl compounds should not receive Mesna. Caution is advised in patients with autoimmune disorders as they may have an increased risk of hypersensitivity reactions.

Clinical Pearls

Diagnostic: Always obtain a baseline urinalysis before starting oxazaphosphorine chemotherapy, and monitor daily (or as per protocol) for micro/gross hematuria. The presence of hematuria despite Mesna indicates inadequate prophylaxis or a very high burden of acrolein.
Treatment:
- Hydration is paramount: Mesna's efficacy is significantly enhanced by vigorous hydration. This combination is the cornerstone of preventing hemorrhagic cystitis.
- Timing is critical: Mesna must be given with or prior to the oxazaphosphorine and continue for a sufficient duration after the chemotherapy is completed to cover the excretion period of urotoxic metabolites.
- IV vs. PO: IV Mesna is preferred for hospitalized patients, especially those with nausea/vomiting or poor absorption. Oral Mesna may be considered for outpatient administration if the patient can tolerate oral intake and for lower intensity regimens. Remember the bioavailability difference (PO Mesna dose is higher).
- Compatibility: Mesna is compatible with ifosfamide and cyclophosphamide in IV solutions; however, administer separately if possible or per pharmacy guidelines.
Pitfalls:
- Inadequate hydration: This is a common reason for prophylactic failure.
- Premature discontinuation of Mesna: Discontinuing Mesna too early, before all urotoxic metabolites are cleared, can lead to delayed hemorrhagic cystitis. Mesna should continue for at least 12-24 hours after the last dose of ifosfamide/cyclophosphamide, or until urinalysis is clear.
- Underdosing: Not administering a sufficient Mesna dose relative to the chemotherapy dose.
- Ignoring patient symptoms: Even with Mesna, patients should be educated on symptoms of hemorrhagic cystitis and advised to report them promptly.

Recent Updates

Guidelines: Current oncology guidelines (e.g., NCCN, ASCO) continue to strongly recommend Mesna for all ifosfamide regimens and high-dose cyclophosphamide. No major changes to Mesna dosing or administration protocols have been widely adopted recently, reinforcing its established role.
Evidence: Ongoing research focuses on optimizing chemotherapy regimens and supportive care. While Mesna's role is well-established, studies may explore new biomarkers for acrolein toxicity or alternative prophylactic strategies, but Mesna remains the gold standard.
Controversies: No significant controversies regarding Mesna's efficacy or safety when used as indicated. Debate primarily centers on the exact cyclophosphamide dose threshold at which Mesna becomes mandatory, varying slightly between institutions and protocols.

Key References

Guidelines:
- National Comprehensive Cancer Network (NCCN) Guidelines for specific cancer types (e.g., Lymphoma, Sarcoma) - these often include supportive care recommendations.
- American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines (e.g., for management of chemotherapy side effects).
Studies:
- Scheef, W., et al. (1987). "Mesna in the prevention of ifosfamide-induced urothelial toxicity: a comprehensive review." Cancer Treatment Reviews, 14(1): 69-79. (Historical landmark reviews)
- Numerous phase II and III clinical trials establishing the efficacy of Mesna with ifosfamide and high-dose cyclophosphamide, often cited in drug prescribing information.
Reviews:
- UpToDate: "Chemotherapy-induced hemorrhagic cystitis"
- Pharmacology textbooks (e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, Katzung's Basic & Clinical Pharmacology)
- Manufacturer's Prescribing Information (e.g., for Mesnex®)